摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Ethoxy-2-methyl-9-propan-2-ylpurine

中文名称
——
中文别名
——
英文名称
6-Ethoxy-2-methyl-9-propan-2-ylpurine
英文别名
6-ethoxy-2-methyl-9-propan-2-ylpurine
6-Ethoxy-2-methyl-9-propan-2-ylpurine化学式
CAS
——
化学式
C11H16N4O
mdl
——
分子量
220.27
InChiKey
WTWBSOHRBLRYTN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    52.8
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    申请人:Girijavallabhan Vinay
    公开号:US20140206640A1
    公开(公告)日:2014-07-24
    The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    本发明涉及式(I)的2'-叠氮基取代核苷衍生物及其药学上可接受的盐,其中B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-叠氮基取代核苷衍生物的组合物,以及使用这些2'-叠氮基取代核苷衍生物治疗或预防患者HCV感染的方法。
  • 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES
    申请人:Girijavallabhan Vinay
    公开号:US20140161770A1
    公开(公告)日:2014-06-12
    The present invention relates to 2′-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Cyano Substituted Nucleoside Derivative, and methods of using the 2′-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    本发明涉及式(I)的2'-基取代核苷衍生物及其药学上可接受的盐,其中B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-基取代核苷衍生物的组合物,以及使用这些2'-基取代核苷衍生物治疗或预防患者HCV感染的方法。
  • 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION
    申请人:Idenix Pharmaceuticals, Inc.
    公开号:US20160083413A1
    公开(公告)日:2016-03-24
    Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.
    本文提供了用于治疗黄病毒科感染,包括丙型肝炎(HCV)感染的化合物、组合物和方法。在某些实施例中,公开了核苷衍生物的化合物和组合物,可以单独或与其他抗病毒药物联合使用。在某些实施例中,化合物是根据公式2001的2'-核苷,或其药学上可接受的盐、溶剂化合物、立体异构体形式、互变异构体形式或多态形式,其中B、Z和PD如本文所述。
  • Cyclic di-nucleotide compounds as sting agonists
    申请人:Merck Sharp & Dohme Corp.
    公开号:US10766919B2
    公开(公告)日:2020-09-08
    A class of polycyclic compounds of general formula (I), of general formula (I′), or of general formula (I″), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    一类通式(I)、通式(I′)或通式(I″)的多环化合物,其中Base1、Base2、Y、Ya、Xa、Xa1、Xb、Xb1、Xc、Xc1、Xd、Xd1、R1、R1a、R2、本文定义的 R2a、R3、R4、R4a、R5、R6、R6a、R7、R7a、R8 和 R8a 可用作 I 型干扰素产生的诱导剂,特别是 STING 活性剂。还提供了合成和使用这些化合物的工艺。
  • 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    申请人:Girijavallabhan Vinay
    公开号:US20140154211A1
    公开(公告)日:2014-06-05
    The present invention relates to 2′-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Substituted Nucleoside Derivative, and methods of using the 2′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
查看更多